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Background: Hepatocyte-like cells (NeoHepatocytes) generated from a peripheral blood monocyte-derived stem
cell-like cell (the PCMO) are a promising alternative for primary hepatocytes in cell transplantation studies to cure
liver diseases. However, to be therapeutically effective NeoHepatocytes are needed in large quantities. It was the
aim of the present study to investigate i) whether the proportion of actively proliferating NeoHepatocytes can be
enhanced by supplementing the PCMO differentiation medium (containing M-CSF, IL-3, and human serum) with
either EGF or HB-EGF and ii) which signaling pathway underlies the promitotic effect.
Results: EGF and HB-EGF enhanced cell proliferation of PCMOs as demonstrated by increased expression of cycle
control genes (ABL, ANAPC2, CDC2, CDK4, CDK6), phosphorylation of the retinoblastoma protein, and increased
PCMO cell numbers after stimulation with EGF or HB-EGF. EGF also raised the number of monocytes expressing the
proliferation marker Ki67. PCMOs expressed the EGF receptors EGFR (ERBB1) and ERBB3, and expression of both
increased during PCMO generation. Phosphoimmunoblotting of PCMOs indicated that both EGF and HB-EGF
activated MEK-1/2 and ERK1/2 in a concentration-dependent fashion with the effect of EGF being more prominent.
EGF treatment further decreased expression of p47phox and increased that of Nanog indicating enhanced
dedifferentiation and pluripotency, respectively. Treatment with both EGF and HB-EGF resulted in NeoHepatocytes
with improved functional parameters.
Conclusions: The results suggested that the addition of EGF or HB-EGF to PCMO differentiation medium
superactivates MEK/ERK signaling which then increases both PCMO proliferation, number, and functional
differentiation of PCMO-derived NeoHepatocytes.
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Although hepatocyte transplantation is a therapeutic op-
tion for end-stage liver diseases, cell material is scarce
due to a critical shortage of liver tissues and the lack of
protocols that allow maintaining the differentiated hep-
atocyte phenotype in culture for more than a week.
Thus, generation of hepatocyte-like cells from stem cells
or stem cell-like cells may represent a promising alterna-
tive [1]. One such cell type with inherent stem cell-like
features is the human peripheral blood monocyte [2-5].
By initially inducing a process of dedifferentiation we
have generated from these cells a more plastic deriva-
tive termed “programmable cell of monocytic origin”
(PCMO). PCMOs are prone to acquire functional activ-
ities of hepatocyte-like cells (NeoHepatocytes) upon
stimulation with appropriate differentiation media
in vitro [2,3], and in vivo following transplantation into
mice [2].
From the clinical point of view, a major obstacle in
cell transplantation is the large amount of cells required
to achieve a therapeutic effect in patients. Despite an
already large number of cells that can be retrieved
from blood products the overall numbers of NeoHepa-
tocytes obtained after the two-step dedifferentiation-
differentiation protocol are still low and insufficient.
One possibility to increase NeoHepatocyte cell num-
bers is by inducing the cells to proliferate. This is
more likely to be possible at or before the PCMO
stage as the NeoHepatocyte differentiation from PCMO
is mutually exclusive with proliferation. Indeed, during
conversion of peripheral blood monocytes into PCMOs,
a process involving dedifferentiation, a fraction of
monocytes resume proliferation in vitro in response
to macrophage-colony stimulating factor (M-CSF),
interleukin-3 (IL-3), and human serum [2]. The extent of
proliferation however, was not sufficient to substantially
increase the overall cellular yield of NeoHepatocytes. If
the rate of proliferation and/or the percentage of mitoti-
cally active monocytes could be enhanced prior to induc-
tion of differentiation, then an increased number of
NeoHepatocytes may be obtained, thereby increasing the
chance for successful NeoHepatocyte transplantations.
Ideally, a modification of the PCMO generation proced-
ure, e.g. by addition of growth-stimulatory factor(s),
should not only enhance mitotic activity but also the
plasticity of PCMOs in such a way that the resulting
NeoHepatocytes become more hepatocyte-like [6]. Inter-
estingly, a subpopulation of human monocytes that
proliferates in vitro in response to M-CSF has been sus-
pected to be less mature and hence more stem cell-like
than other monocytes [7]. Therefore, the identification
of growth factor signaling pathways that regulate prolif-
eration of human monocytes may enhance both the
quantity and quality of PCMO-derived NeoHepatocytes.Epidermal growth factor (EGF) is known to induce
proliferation in many kinds of cells [8-11] and its recep-
tor is over-expressed in proliferative cells [12]. Another
member from the EGF family, the 20–22 kDa glycopro-
tein Heparin-binding epidermal growth factor (HB-EGF)
[13] was also reported to be a potent mitogen for many
cell types [14-16]. Human peripheral blood monocytes
were shown recently to express a functional EGF recep-
tor (EGFR) [17,18], while the EGF receptors c-ERBB2, 3
and 4 have not been studied. However, a link between
EGF or HB-EGF and proliferation in monocytes has
never been investigated. Analysis of the mechanism of
receptor tyrosine kinase activation in monocytes may
identify soluble factors that control PCMO self renewal.
The present study aimed to investigate the expression
and the activity of the epidermal growth factor receptor
(ERBB) family in human peripheral monocytes and the
role of EGF and HB-EGF on the outcome of PCMO
generation and the subsequent differentiation into
NeoHepatocytes.
Results
Gene expression of EGF receptor family members in
PCMOs
We first sought to determine which EGF receptors are
expressed in monocytes. For this purpose, RNA was iso-
lated from monocyte cultures and processed for qPCR
using primers for EGFR (also termed ERBB1), ERBB2,
ERBB3, and ERBB4 as listed in Table 1. RT-PCR analysis
of the four EGF receptors yielded a strong signal for
EGFR and a weaker one for ERBB3 (Figure 1A). Since
monocytes may be “contaminated” with lymphocytes, a
negative control sample of highly purified lymphocytes
was analyzed in parallel and shown to lack expression of
both EGFR and ERBB3 (data not shown). This indicated
that the amplification products for EGFR and ERBB3
were specifically derived from monocytes. Since the ex-
pression levels of some genes may differ during the de-
velopment of PCMOs in culture, we isolated RNA from
the developing PCMOs at different days of culture. The
qPCR of these samples indicated that expression of both
EGFR and ERBB3 initially increased during PCMO gen-
eration reaching a peak on the second day (ERBB3) and
on the fourth day (EGFR) of culture and decreased
thereafter (Figure 1B).
EGF promotes proliferation during PCMO production
Next, we examined the effect of EGF and HB-EGF on
the proliferation of PCMOs (Figure 2). For this purpose,
cells were cultured for 4 days in PCMO medium con-
taining EGF or HB-EGF at different concentrations.
Cells were prepared for immunofluorescence using Ki67
antibody as a proliferation marker and CD14 as a mono-
cyte marker. The results showed a higher number of
Table 1 Sequences of PCR primers
Gene Accession No. Sense primer Antisense primer Product size (bp)
EGFR NM_005228.3 ATGCTCTACAACCCCACCAC GCCCTTCGCACTTCTTACAC 193
c-erbB2 NM_004448.2 CCCTCATCCACCATAACACC GCCTGGCATTCACATACTCC 279
c-erbB3 NM_001982.3 TACTTGGAACGGGGTGAGAG ACTCTGCCGTCCACTCTTGT 219
c-erbB4 NM_005235.2 AGTCAGTGTGTGCAGGAACG CTCCAGAGGCAGGTAACGAA 224
Nanog NM_024865 GATTTGTGGGCCTGAAGAAAACT AGGAGAGACAGTCTCCGTGTGAG 79
GAPDH NM_002046 TTGCCATCAATGACCCCTTCA CGCCCCACTTGATTTTGGA 174
β-actin NM_031144 GATATCGCTGCGCTCGTC TCCATATCGTCCCAGTTGG 239
ANAPC2 NM_013366.3 CCAGTACAGGCGGTGATCTT GCTCTCGTCGTCACTGTCAA 228
ABL-1 NM_005157.4 AACACCCTAACCTGGTGCAG CAAGTGGTTCTCCCCTACCA 248
CDC2 (CDK1) NM_001786.4 GGGGTCAGCTCGTTACTCAA GATGCTAGGCTTCCTGGTTTC 225
CDK4 NM_000075.2 CTGACCGGGAGATCAAGGTA AGCCAGCTTGACTGTTCCAC 224
CDK6 NM_001145306.1 TCCCAGGAGAAGAAGACTGG GGTCCTGGAAGTATGGGTGA 198
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EGF-treated cultures (Figure 2a). However, quantifica-
tion of these cells showed that the HB-EGF but not the
EGF effect closely missed statistical significance
(Figure 2B). No statistically significant differences of
Ki67/CD14-positive cell counts were observed amongB
EGFR      ERBB2    ERBB3    ERBB4     β-actin
1                2                3               4               5              6
A
Figure 1 Detection of different EGF receptor family members
by RT-PCR in human blood monocytes. (A) Standard endpoint
RT-PCR of EGFR (lane 2), ERBB2 (lane 3), ERBB3 (lane 4), ERBB4 (lane
5), and β-actin as control (lane 6) in PCMOs. RNA was isolated from
day-4 PCMOs and reverse-transcribed. Amplification products of the
resulting cDNA (using the primers listed in Table 1) were run on an
agarose gel and stained with ethidiumbromide. A molecular weight
marker (lane 1) was run in parallel to confirm the predicted band
sizes. (B) QPCR analysis of the same EGF receptors in monocytes
during the generation of PCMOs. Data shown are the mean± SD of
3 separate experiments performed in duplicates.different concentrations of the same treatment. These
data clearly show that the addition of EGF enhanced the
proliferative activity of monocytes in PCMO generation
medium. EGF-induced proliferation temporally corre-
lated with cell cycle activation. In order to investigate
whether EGF-induced proliferation was associated with
the expression of specific cell-cycle regulatory genes, we
treated monocytes with different concentrations of EGF
or HB-EGF and performed qPCR analysis as described
in the Methods section. As seen in Table 2, both EGF
and HB-EGF up-regulated the expression of ABL,
ANAPC2, CDC2, CDK4, and CDK6, each of which is
involved in different stages of the cell cycle.
RNA was isolated from PCMOs after 4-day culture with
or without EGF or HB-EGF (10, 50, 100 μg/L) and tran-
scribed to cDNA. QPCR was applied using primer pairs
listed in Table 1. Data are presented as mean±SEM of
N=4 and represent the fold-change in comparison with
control PCMOs (cultured without HB-EGF or EGF), the
values of which were considered as 1. Statistical analysis:
a = significantly different from the control, b: significantly
different from the corresponding HB-EGF value.
The retinoblastoma protein (pRb) plays a pivotal role
in the negative control of the cell cycle and prevents the
cell from replicating damaged DNA by blocking progres-
sion through G1 into S phase. Its inhibitory role on cell
cycle progression is carried out in the hypophosphory-
lated state, while phosphorylation inactivates pRb [19].
We have analysed the phosphorylation state of pRb in
PCMOs generated in the presence of either EGF or HB-
EGF (Figure 2C). The results show that treatment with
HB-EGF increased the phosphorylation of pRb, while
EGF caused its hyperphosphorylation. In control cells,
however, only the active non-phosphorylated form was
present (Figure 2C).
We have also investigated cyclin A protein in the same




Figure 2 EGF and HB-EGF increase the number of mitotically active cells in PCMO cultures. (A) immunofluorescence of Ki67 expression
(red) in PCMO cultures treated for 4 days with the indicated concentrations of either EGF or HB-EGF. PCMOs were immunostained with CD14
(green) as a monocyte-specific marker. Nuclei were stained with DAPI (blue). (B) Quantification of Ki67 expressing PCMOs after treatment with
EGF or HB-EGF. Data (N= 3) are expressed as mean± SEM. Statistical analysis: “a” denotes a significant difference from the control; “b” denotes a
significant difference from the corresponding values of HB-EGF. (C) Immunoblotting of the retinoblastoma protein and cyclin A in PCMO cultures
treated for 4 days with the indicated concentrations (in μg/L) of either HB-EGF or EGF. The housekeeping protein β-actin was detected as a
loading control. Densitometric analysis of cyclin A and β-actin bands was performed using NIH ImageJ software (version 1.45). The indicated
values below the blots represent the normalized signal intensities for cyclin A relative to untreated control cells set at 1. (D) PCMO cell counts
after 4 days of culture with 10 μg/L of either EGF or HB-EGF (N= 3). Statistical analysis: “a” denotes a significant difference from the control.
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tinct cyclin A kinase activities, one appearing in S phase
and the other one in G2 phase [20]. Immunoblotting
indicated an increase in cyclin A expression uponTable 2 Expression of cell cycle genes during the developmen
ABL ANAPC2
Hb-EGF 10 1.40 ± 0.19a 1.74 ± 0.62
Hb-EGF 50 1.26 ± 0.15a 1.40 ± 0.45
Hb-EGF 100 1.48 ± 0.43 1.63 ± 0.66
EGF 10 2.24 ± 0.18ab 1.78 ± 0.43
EGF 50 1.69 ± 0.20ab 1.70 ± 0.42
EGF 100 1.74 ± 0.30ab 1.60 ± 0.38
ANOVA = 0.0033 0.0748treatment of PCMOs with 50 and 100 μg/L HB-EGF and
with all three concentrations of EGF (Figure 2C).
Finally, we performed cell counting of PCMOs cul-
tured for 4 days with either 10 μg/L EGF or HB-EGFt of PCMOs cultured in the presence of HB-EGF or EGF
CDC2 CDK4 CDK6
1.88 ± 0.74 1.53 ± 0.33 2.42 ± 1.10
1.81 ± 0.77 1.56 ± 0.33 2.09 ± 0.80
2.23 ± 0.95 1.47 ± 0.27 2.35 ± 1.06
3.01 ± 1.05ab 1.57 ± 0.17 2.47 ± 0.96
1.99 ± 0.42a 1.39 ± 0.10 2.15 ± 0.87
2.02 ± 0.50a 1.53 ± 0.14 2.38 ± 0.93
0.036 0.261 0.0756
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significant increase over the control in total cell counts
after both treatments. No difference was observed be-
tween the two treatments. Together, the data show that
EGF and HB-EGF are suitable tools to expand the total
cell number of PCMOs and that this largely occurs
through an increase in the mitotic/cell cycle activity of
monocytes.EGF treatment attenuates expression of p47phox and
enhances expression of Nanog in PCMOs
During the generation of PCMOs, monocytes downregu-
late markers of differentiation, e.g. p47phox an essential
subunit of the reactive oxygen producing enzyme NAD
(P)H oxidase and upregulate markers of pluripotency,
e.g. Nanog [6]. We have examined the effect of EGF
and HB-EGF on the expression of p47phox by immuno-
blotting (Figure 3A) and on the expression of Nanog by
qPCR (Figure 3B). The p47phox protein levels were
clearly lower on day 4 of culture which was particularly



















































Figure 3 Regulation of Nanog and p47phox expression by EGF
or HB-EGF in PCMOs. (A) Measurement of Nanog expression by
qPCR in PCMOs treated for 4 days with the indicated concentrations
(in μg/L) of HB-EGF or EGF. Data (mean± SEM, N= 4) were
normalized to the expression level of GAPDH. ANOVA: p < 0.01;
a = all values of EGF and HB-EGF are significantly higher than that of
the control; b = significant difference between EGF and the
corresponding HB-EGF value. (B) Immunoblot analysis of p47phox in
day-4 PCMOs treated with either HB-EGF or EGF at the indicated
concentrations. The β-actin protein was detected as a loading
control.differences were observed between treatments with dif-
ferent concentrations of EGF. Both EGF and HB-EGF
caused a more than 2-fold increase in the mRNA levels
of Nanog (Figure 3B). Statistically significant differences
were observed neither among EGF and HB-EGF treat-
ments nor among different concentrations of each
growth factor. The data suggest that EGF can enhance
both the extent of dedifferentiation and pluripotency.
MEK/ERK signaling drives proliferation in PCMOs and is
superactivated by EGF and HB-EGF
ERK and MEK activation is involved in M-CSF and
EGF-induced proliferation of PCMOs. We have previ-
ously shown that during PCMO culture, a subset of
monocytes resumes proliferation. To test whether this is
associated with activation of MEK/ERK signaling, we
performed immunoblot analysis of ERK activation
(Figure 4A). ERK phosphorylation during PCMO gener-
ation peaked on day 3–4 of culture and this increase
coincided with peak mitotic activity [2]. This suggested
that ERK activation is causally involved in driving prolif-
eration of monocytes/PCMOs. To test this more dir-
ectly, we inhibited MEK1 with U0126 during PCMO
culture and assessed the number of cells on day 6. The
total number of cells was low, indicating that MEK/ERK
signaling is crucial for PCMO proliferation (Figure 4B).
Since both EGF and HB-EGF are known to stimulate
ERK activation, we reasoned that these agents may en-
hance proliferation by superactivating the MEK/ERK
pathway. To test this prediction, PCMOs were generated
in standard PCMO differentiation medium in the ab-
sence or presence of either EGF or HB-EGF and sub-
jected to immunoblot analysis of phospho-MEK and
phospho-ERK. The results indicated that both EGF and
HB-EGF activated MEK and ERK and that the effect was
concentration-dependent and more prominent in EGF-
treated than in HB-EGF-treated PCMOs (Figure 4C).
Effect of EGF and HB-EGF on NeoHepatocyte function
Ideally, a modification of the PCMO generation proced-
ure should not only enhance proliferation but also the
stem cell features of PCMOs in a way that the resulting
NeoHepatocytes become more hepatocyte-like. We
therefore tested whether adding EGF and HB-EGF to
the PCMO generation medium would alter functional
parameters of the Neoepatocytes. Control PCMOs and
PCMOs generated in the presence of either EGF or HB-
EGF were allowed to differentiate into NeoHepatocytes
for 2 weeks and at the end of this period were analysed
for hepatocyte-specific functions (Figure 5).
NeoHepatocytes, regardless of treatment, including
the control, formed and secreted urea in similar
amounts as under basic conditions. Addition of NH4Cl
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Figure 4 MEK/ERK signaling drives proliferation in PCMOs and is superactivated by EGF and HB-EGF. (A) M-CSF and Il-3 induce
phosphorylation of ERK (pERK). Protein samples were obtained from PCMOs cultured for various days (as indicated) in standard PCMO
differentiation medium. (B) Inhibition of ERK was sufficient to inhibit PCMO proliferation. Cells were cultured with either solvent (left) or the ERK
inhibitor U0126 (right) for 6 days and images were taken. Original magnification: 50x. (C) HB-EGF and EGF induce phosphorylation of MEK and
ERK. Phospho-MEK (p-MEK), MEK1/2, phospho-ERK (p-ERK), and ERK1/2 expression was examined by immunoblotting in lysates of day-4 PCMOs
that have been treated with the indicated concentrations of either HB-EGF or EGF.
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ated in the presence of HB-EGF. NeoHepatocytes re-
gardless of treatment, including the control, all secreted
glucose at similar rates. To measure the ability of the
cells to perform gluconeogenesis, the Na-pyruvate-
containing incubation buffer was supplemented with
Na-L-lactate. Stimulation with pyruvate/lactate induced
higher glucose secretion compared to non-stimulated
cultures. As for urea, the effect was higher in NeoHepa-
tocytes obtained from PCMOs generated in the presence
of HB-EGF.
NeoHepatocytes exhibit phase I and II enzyme activ-
ities. However, levels were significantly lower compared
to primary human hepatocytes [21] and could be
enhanced by replacing the FCS with autologous serum
[21]. We investigated the effect of EGF and HB-EGF on
the activity of three different cytochrome P450 isoforms
(1A1/2, 2D6, and 3A4) and a phase II enzyme (UDP-
glucuronosyl-transferase). The activities measured in
cells varied between the different treatments. CYP1A1/2
activity was similar in, NeoHepatocytes obtained from
PCMOs treated with either EGF or HB-EGF, and the
effect of both was concentration-dependent. CYP2D6
activity was higher in NeoHepatocytes obtained from
PCMOs treated with HB-EGF than those treated with
EGF. This situation was reversed for the activity of
CYP3A4. The activity of the phase II enzyme UDP-
glucuronosyl-transferase was similar for both treat-
ments, but higher than that of the control.Discussion
Peripheral blood monocytes can be reprogrammed to
generate a kind of stem cell-like cell (PCMO), which is
sensitive to differentiation into hepatocyte-like cells
[2,3]. In view of a potential clinical use of these cells in
regenerative cell therapies such as treatment of end-
stage liver diseases, the identification of factors capable
of increasing the expansion of PCMOs/NeoHepatocytes
is of great importance.
M-CSF and IL-3 present in the PCMO generation
medium induce a proliferative response in a subset of
monocytes through activation of MEK/ERK1/2 signaling
(see Figure 4). Since this signaling pathway is also acti-
vated by EGF and HB-EGF and their receptors and is
involved in the proliferation of many cell types [14-16],
we reasoned that EGF should be able to further stimu-
late PCMO proliferation. In agreement with this as-
sumption, we detected the expression of EGFR and
ERBB3 in monocytes. The expression of both receptors
gradually increased during monocyte/PCMO culture,
suggesting a role for them in the process of PCMO gen-
eration. Activation of EGFR on monocytes has been
reported to be required for monocyte activation and cel-
lular motility [17]. EGF was found also to mediate
monocyte chemotaxis and macrophage proliferation
[18]. Taking advantage of the relative ability of monocyte
subpopulations to undergo proliferation and generate
PCMOs, we showed here that EGF and HB-EGF were






































































































































































Figure 5 Effect of EGF and HB-EGF treatment during PCMO culture on NeoHepatocyte function. PCMOs treated with the indicated
concentrations (in μg/L) of EGF or HB-EGF were cultured in hepatocyte conditioning medium for 2 weeks before subjecting them to analysis of
cytochrome P450 (CYP) isoforms 1A1/2 (A), 2D6 (B), and 3A4 (C), the phase II enzyme UDP-glucuronosyl transferase (D), urea metabolism (E), and
glucose metabolism (F). Methodologic details are given in the Methods section. Data are presented as mean± SEM of N= 4. Statistical analysis:
Single-Factor ANOVA: p < 0.01 for A, B and D; ANOVA (2-Factor with replication) for E: p < 0.001 between different EGF/HB-EGF treatments;
p < 0.001 between basal and NH4Cl-treatments; for F: p < 0.001 between basal and pyruvate + lactate treatments; a = significantly different vs.
control; b = vs. corresponding HB-EGF value; c = vs. basal value.
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respect to Ki67 staining the HB-EGF effect did not reach
statistical significance, which may be explained by
donor-specific variations in the monocyte’s ability to re-
spond to various treatments in culture (H.U., unpub-
lished observation). The enhanced proliferation was
accompanied by activation of cell cycle regulatory genes
ANAPC2, ABL1, CDK4, CDK6, and CDC2. ANAPC2
plays an important role in the regulation of the G1/S
and G2/M transitions while ABL1 regulates the S-phase
and DNA replication. CDK4 and 6 participate in the G1/
S transition and CDC2 in M-phase regulation. EGF was
also previously reported to induce increased cyclin D1
expression in other systems [22]. Inhibition of some of
the functional proteins such as ANAPC2 and CDC2 that
form the anaphase promoting complex/cyclosome
(APC/C) has been reported to induce cell cycle arrest at
G2/M [23]. Thus, the induction of cell cycle arrest is
associated with the down-regulation of genes involved in
G1/S and G2/M transitions and an increase in the ex-
pression of these genes can lead to activation of the cell
cycle. We confirmed these results by immunoblotting of
pRb, which negatively regulates progression from G0through to G1 and into S phase [24]. The results showed
that treatment with EGF increased the pRb hyperpho-
sphorylated form to a greater extent than HB-EGF
which also showed a higher degree of phosphorylation
than the control. pRb is normally hypophosphorylated in
resting cells at G0 when proliferation is repressed. Upon
activation of the cell cycle, appropriate signals lead to
the subsequent activation of the cyclin D/CDK4 and 6,
cyclin E/CDK2 and cyclin A/CDK2 complexes, which in-
creasingly phosphorylate pRb during progression
through G1. The pRb will be kept in a hyperphosphory-
lated (inactive) form until late in mitosis [25].
In contrast to GM-CSF [26], M-CSF and IL-3 induced
tyrosine phosphorylation and activation of ERK in mono-
cytes. Moreover, addition of the MEK inhibitor U0126
prevented M-CSF+ IL-3-induced proliferation, strongly
suggesting that MEK/ERK signaling drives the prolifera-
tive response of monocytes under standard culture con-
ditions. In the present work, we demonstrated that
addition of EGF or HB-EGF superactivated the MEK/
ERK pathway and further increased proliferation. In
other systems, the EGFR tyrosine kinase inhibitor Erloti-
nib, and U0126 completely inhibited EGF-induced
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ation of Akt and ERK, implying a role for phosphatidyli-
nositol 3-kinase (PI3K)/Akt and MEK/ERK signaling in
HB-EGF-stimulated cell proliferation [16]. The PI3K
inhibitors LY294002 and wortmannin, and the MEK/
ERK inhibitors U0126 and PD98059, reduced HB-EGF-
induced BrdU incorporation into cultures [16]. Taken to-
gether, it can be concluded that exposure of PCMOs to
EGF or HB-EGF leads to activation of their receptors
(ERBB1 and 3), the expression of which increases during
PCMO culture, and subsequent activation of MEK/ERK.
This extra input of ERK signaling is sufficient to further
enhance PCMO proliferation beyond the level achieved
with M-CSF+ IL-3-induced ERK activation.
Our results showed that both EGF and HB-EGF acti-
vated cell proliferation-associated changes in PCMOs
during their generation but that these effects were gen-
erally stronger for EGF. Nevertheless, treatment with
both agents resulted in the same increase in total PCMO
cell numbers. This suggests the possibility that HB-EGF,
in addition to its growth-promoting function, exerts
anti-apoptotic effects on PCMOs that contribute to cell
expansion.
Interestingly, EGF and HB-EGF appear to enhance de-
differentiation of PCMOs (as assessed by a decrease in
the expression of p47phox) and to increase pluripotency
(as assessed by an induction of Nanog) [6]. We have pre-
viously characterized stem cell marker expression in
PCMOs and have demonstrated similar expression pro-
files of Nanog and Oct3/4 during PCMO generation [6].
Moreover, the expression of Nanog and Oct3/4 was par-
alleled by a global rise in histone H3 methylation on
Lys-4, a marker of active chromatin, and coincided with
peak sensitivity to hepatocyte-specific differentiation [6].
Functionally, both EGF and HB-EGF applied during
PCMO generation improved the function of the result-
ing NeoHepatocytes when compared with those derived
from control (standard) PCMOs. However, the present
results demonstrated functional similarities of NeoHepa-
tocytes obtained after PCMO treatment with either EGF
or HB-EGF. When EGF and HB-EGF where compared
for their potency to enhance the hepatocyte-specific
functions of NeoHepatocytes no major differences were
observed, although HB-EGF appears to be superior with
respect to urea production, glucose metabolism and
CYP2D6 activity, while EGF was superior in inducing
CYP3A4 activity.
Conclusions
The present data reveal that EGF and HB-EGF improve
the proliferation of PCMOs by superactivating MEK/
ERK signaling. Notably, however, both factors improve
hepatocyte-specific functions of the resulting NeoHepa-
tocytes which is an important issue when consideringthese cells for transplantation purposes. Based on these
data, we suggest modifying the current protocol of




Human peripheral blood monocytes isolated from LRS
chambers or buffy coats from healthy donors were iso-
lated by density gradient centrifugation and further puri-
fied by adherence separation. Cells (1 x 105/cm2) were
allowed to adhere to tissue culture plastics for 1–2 h in
RPMI 1640 medium containing 10% human AB serum
(Lonza, Cologne, Germany), 2 mmol/L glutamine, 100
U/mL penicillin, and 100 μg/mL streptomycin (all from
Invitrogen, Karlsruhe, Germany). Nonadherent cells
were removed by aspiration, and the adherent mono-
cytes were cultured for 4 days in dedifferentiation
medium consisting of RPMI supplemented with
140 μmol/L 2-mercaptoethanol, 5 μg/L M-CSF, and
0.4 μg/L human IL-3 (both from R&D Systems, Wies-
baden, Germany)). In previous experiments these cells
have been tested for purity by flow cytometry analysis of
CD45 and CD14, typically yielding a purity of 70-80%
[2]. Either EGF or HB-EGF (both from R&D Systems)
was added to the dedifferentiation medium at various
concentrations (10, 50, or 100 μg/L). The MEK inhibitor
U0126 was purchased from Calbiochem/Merck (Darm-
stadt, Germany) and dissolved in dimethyl sulfoxide.
Differentiation of PCMOs into NeoHepatocytes
After 4 days of culture in dedifferentiation medium
PCMOs were cultured for 2 weeks with hepatocyte con-
ditioning medium (RPMI 1640 medium containing 3 μg/
L fibroblast growth factor-4 (FGF-4, R&D Systems) and
10% FBS) for differentiation into NeoHepatocytes [2].
The medium was changed every 3 days. Cells were then
subjected to analysis of hepatocyte function.
Immunofluorescence
PCMOs were washed with PBS, centrifuged and diluted
with PBS containing 1% BSA, centrifuged at maximal
speed for 3 min using the Cytospin 4 centrifuge (Thermo
Scientific) and kept in −20°C until needed. For prolifera-
tive cell staining, slides were fixed in 1% paraformalde-
hyde, blocked for 1 h and then incubated with
anti-human CD14 antibody (BD Biosciences, Heidel-
berg, Germany) at room temperature for 2 h and Alexa-
fluor 488–labeled secondary antibody (Invitrogen) for
1 h. After washing, cells were permeabilized using 0.5%
triton X-100 and incubated overnight with the anti-
human Ki67 (BD Pharmingen) at 4°C followed by
Alexafluor 555-labeled secondary antibody (Invitrogen).
Ki67-positive cells were counted double-blind by two
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for all experiments (N=4) and related to the total cell
count of CD14-positive monocytes in the same field.
RNA isolation and quantitative RT-PCR
Total RNA isolation from PCMOs, human peripheral
blood monocytes and autologous lymphocytes (purified
by elutriation as described earlier [6]) was performed
using the GeneJet purification kit (Fermentas, St. Leon-
Rot, Germany). To assure absence of genomic DNA, all
RNA samples were treated with DNase I, and primers
spanning multiple exon-intron boundaries were used.
For reverse transcription, 1 μg of the total RNA was re-
verse transcribed to first strand complementary DNA
using the High-Capacity reverse transcription kit (Ap-
plied Biosystems, Darmstadt, Germany). Gene expres-
sion was quantified by standard endpoint RT-PCR and
standard real-time RT-PCR (qPCR) on an iCycler (Bio-
Rad, Munich, Germany) and analyzed by agarose gel
electrophoresis and iCycler iQ Real-Time Detection Sys-
tem software (Bio-Rad), respectively. The thermal cyc-
ling program was 10 min at 95°C for enzyme activation,
denaturation for 15 s at 95°C, 60 s annealing at 60°C,
and 60 s extension at 72°C. A dissociation curve was
performed for each product to assure the absence of pri-
mer dimers or unspecific products. Primers used in the
present study are listed in Table 1. Relative quantifica-
tion was performed by ΔΔCt method. To normalize ex-
pression data, amplification of the housekeeping gene
GAPDH was used as an internal control.
Western blotting
Following 4 days of PCMO generation, cells were thor-
oughly washed with PBS to remove non-adherent cells
(mainly T lymphocytes) and lysed using PhosphoSafe
lysis buffer (Novagen/Merck). Cell lysates were separated
by electrophoresis prior to transfer to PVDF membranes
(Immobilon P). Membranes were then probed with pri-
mary antibodies and immunoreactive bands were
detected by chemiluminescence. Primary antibodies used
were MEK1 (C-18), MEK2 (C-16), p-MEK1/2 (Ser218/
Ser222), ERK1 (C-16), p-ERK (Tyr 204) (all from Santa
Cruz Biotechnology, Heidelberg, Germany), anti-human
pRb (BD Pharmingen), and β-actin (Sigma, Deisenhofen,
Germany). Secondary antibodies were obtained from GE
Healthcare (Buckinghamshire, UK).
Analysis of NeoHepatocyte function
Urea measurement: To remove residual urea from the
culture medium, cells were washed twice with DPBS. To
determine basal levels of urea formed, cells were incu-
bated with DPBS (1 mM MgCl2, 1 mM Na-pyruvate) for
24 h. To measure the ability of the cells to metabolize
ammonium, the buffer was supplemented with 5 mMNH4Cl ± 1 mM ornithine. Supernatant (80 μl) was incu-
bated with 60 μl 0.0002% O-phthaldehyde solution
(0.03% Brij-35, 7.4 % H2SO4) and 60 μl NED reagent
[0.0006%N-(1-naphthyl)ethylenediamine dihydrochlor-
ide, 0.5% boric acid, 0.03% Brij-35, 22.2% H2SO4] for 2 h
at 37°C. Absorbance was measured at 505 nm and com-
pared to standard samples [21].
Glucose measurement: Cells were washed three
times with DPBS before incubation for 24 h with
DPBS (30 mM KCl, 1 mM MgCl2, 1 mM Na-
pyruvate ± 10 mM Na-L-lactate). Supernatant (100 μl)
was incubated with 150 μl GLOX solution (250 mM
Tris, 0.2 mM EDTA, 0.04% glucose-oxidase, 0.007%
peroxidase, 0.01% O-dianisidine, pH 8.0) for 2 h at 37°C.
Absorbance was measured at 420 nm and compared to
standard samples.
Phase I and II Enzyme activity assays: Fluorescence-
based cytochrome P450 assays were performed by incu-
bation of intact cells with selected substrates as reported
[21]. Briefly, cells cultured on a 96-well plate were serum
starved (RPMI 1640 medium without supplements) over-
night prior to measurement. For measurement the medium
was replaced with 100 μl reaction buffer (plain RPMI 1640
medium containing the fluorogenic substrates: 25 μmol/L
7-ethoxy coumarin for CYP1A1/2, 10 μmol/L AMMC
(3-[2-(N,N-diethyl-N-methylamino)ethyl]-7-methoxy-4-
methylcoumarin) for CYP2D6, 10 μmol/L BFC (7-
benzyloxy-4-trifluoromethylcoumarin) for CYP3A4 and
100 μmol/L 4-methylumbelliferon as a substrate for UDP-
Glucuronosyl-transferase). Fluorescence was measured
every 10 min over a period of 2 h with a microplate reader
(BMG Labtech, Offenburg, Germany). Afterwards cells
were fixed for protein quantification by sulforhodamine B
(SRB) staining as previously described [27]. Results are
given as pmol of fluorescent product formed (phase I
enzyme activities) or fluorescent substrate reduced (for
phase II enzyme activities) per minute normalized to
total protein content in mg.
Statistical analysis
All samples were measured in duplicates. Values were
expressed as mean± SEM. with N=4 in all experiments.
Group statistical comparisons were performed by one-
way or two-way analysis of variances (ANOVA) followed
by Mann–Whitney multi-range analysis as a post-hoc
test. The p values were shown in the Results section A
statistical difference was considered significant if
p < 0.05.
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